Long-term changes in cyclosporine pharmacokinetics after renal transplantation in children: Evidence for saturable presystemic metabolism and effect of NR1I2 polymorphism

Journal of Clinical Pharmacology

Volumn 50, Issue 5, 2010, Pages 581-597

  Fanta, Samuel ^a,b   Jönsson, Siv ^b,c   Karlsson, Mats O ^b   Niemi, Mikko ^a   Holmberg, Christer ^b   Hoppu, Kalle ^a,b   Backman, Janne T ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF HELSINKI   (Finland)

^c MEDICAL PRODUCTS AGENCY   (Sweden)

Author keywords

Cyclosporine; Pediatric renal transplantation; Pharmacogenetics; Population pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; GELATIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; NANOCARRIER;

ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CHILD; CONGENITAL NEPHROTIC SYNDROME; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CLEARANCE; DRUG FORMULATION; DRUG METABOLISM; GENE FREQUENCY; GENOTYPE; HAPLOTYPE; HEREDITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MICROEMULSION; MORNING DOSAGE; NEPHRONOPHTHISIS; PHARMACOGENETICS; PRESCHOOL CHILD; QUANTITATIVE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; AGE FACTORS; ALLELES; BIOLOGICAL AVAILABILITY; BODY WEIGHT; CAPSULES; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; EMULSIONS; FOLLOW-UP STUDIES; HAPLOTYPES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; KIDNEY TRANSPLANTATION; MODELS, BIOLOGICAL; POLYMORPHISM, GENETIC; RECEPTORS, STEROID; TIME FACTORS; YOUNG ADULT;

EID: 77951188222     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009348223     Document Type: Article

References (52)

1. Tönshoff B., Höcker B. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity. Pediatr Transplant. 2006 ; 10: 721-729. (Pubitemid 44186295)
2. Kahan BD Therapeutic drug monitoring of cyclosporine: 20 years of progress. Transplant Proc. 2004 ; 36 (suppl): 378S - 391S. (Pubitemid 38373896)
3. Buell JF, Gross TG, Thomas MJ, et al. Malignancy in pediatric transplant recipients. Semin Pediatr Surg. 2006 ; 15: 179-187.
4. McDonald RA, Smith JM, Ho M., et al. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant. 2008 ; 8: 984-989. (Pubitemid 351537758)
5. Srinivas TR, Meier-Kriesche HU Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result. Clin J Am Soc Nephrol. 2008 ; 3 (suppl 2). S101 - S116.
6. Matas AJ Resolved: in minimizing kidney transplant immunosuppression, steroids should go before calcineurin inhibitors: pro. J Am Soc Nephrol. 2007 ; 18: 3026-3028.
7. Cooney GF, Habucky K., Hoppu K. Cyclosporin pharmacokinetics in paediatric transplant recipients. Clin Pharmacokinet. 1997 ; 32: 481-495. (Pubitemid 27243649)
8. del Mar Fernandez De Gatta M., Santos-Buelga D., Dominguez-Gil A., Garcia MJ Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations. Clin Pharmacokinet. 2002 ; 41: 115-135. (Pubitemid 34264038)
9. Fanta S., Jönsson S., Backman JT, Karlsson MO, Hoppu K. Developmental pharmacokinetics of ciclosporin: a population pharmacokinetic study in paediatric renal transplant candidates. Br J Clin Pharmacol. 2007 ; 64: 772-784.
10. Holford NH A size standard for pharmacokinetics. Clin Pharmacokinet. 1996 ; 30: 329-332.
11. Akhlaghi F., Trull AK Distribution of cyclosporin in organ transplant recipients. Clin Pharmacokinet. 2002 ; 41: 615-637.
12. Kuehl P., Zhang J., Lin Y., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001 ; 27: 383-391.
13. Goldberg H., Ling V., Wong PY, Skorecki K. Reduced cyclosporin accumulation in multidrug-resistant cells. Biochem Biophys Res Commun. 1988 ; 152: 552-558.
14. Schwab M., Eichelbaum M., Fromm MF Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol. 2003 ; 43: 285-307. (Pubitemid 37372643)
15. Fanta S., Niemi M., Jönsson S., et al. Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. Pharmacogenet Genomics. 2008 ; 18: 77-90.
16. Talaulikar GS, John GT, Selvakumar R., Job V., Thomas PP, Jacob CK Pre- and postrenal transplantation pharmacokinetics of cyclosporine microemulsion. Transplant Proc. 2003 ; 35: 1295-1297.
17. Cooney GF, Heifets M., Bell A., Shaw LM, LiBetti G. Utility of pretransplantation cyclosporine pharmacokinetic studies. Ther Drug Monit. 1994 ; 16: 151-154.
18. Wilms HW, Straeten V., Lison AE Different pharmacokinetics of cyclosporine A early and late after renal transplantation. Transplant Proc. 1988 ; 20 (suppl 2). 481-484.
19. Nolin TD, Naud J., Leblond FA, Pichette V. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther. 2008 ; 83: 898-903.
20. Aarons L. Population pharmacokinetics: theory and practice. Br J Clin Pharmacol. 1991 ; 32: 669-670.
21. Hoppu K., Koskimies O., Holmberg C., Hirvisalo EL Pharmacokinetically determined cyclosporine dosage in young children. Pediatr Nephrol. 1991 ; 5: 1-4.
22. Lindbom L., Pihlgren P., Jonsson EN PsN-Toolkit: a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005 ; 79: 241-257.
23. Jonsson EN, Karlsson MO Xpose: an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999 ; 58: 51-64.
24. Manly BFJ. Randomization, bootstrap and Monte Carlo methods in biology. In: Chatfield C, Zidek JV, eds. Texts in Statistical Science. London: Chapman & Hall ; 1997.
25. Efron B., Tibshirani R. An Introduction to the Bootstrap. New York: Chapman & Hall ; 1993.
26. Karlsson MO, Holford NH A tutorial on visual predictive checks. Presented at: 17th meeting of the Population Approach Group in Europe ; June 18-20, 2008 ; Marseille, France.
27. Karlsson MO, Sheiner LB The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm. 1993 ; 21: 735-750.
28. Ette EI, Chu H-M., Ahmad A. Data imputation. In: Ette EI, Williams PJ, eds. Pharmacometrics: The Science of Quantitative Pharmacology. New York: Wiley-Interscience ; 2007: 1216.
29. Tufveson G., Odlind B., Sjoberg O., et al. A longitudinal study of the pharmacokinetics of cyclosporine A and in vitro lymphocyte responses in renal transplant patients. Transplant Proc. 1986 ; 18 (suppl 5). 16-24.
30. Jacobson PA, Ng J., Green KG, Rogosheske J., Brundage R. Posttransplant day significantly influences pharmacokinetics of cyclosporine after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2003 ; 9: 304-311.
31. Wu KH, Cui YM, Guo JF, et al. Population pharmacokinetics of cyclosporine in clinical renal transplant patients. Drug Metab Dispos. 2005 ; 33: 1268-1275.
32. Felipe CR, Silva HT Jr, Machado PG, Garcia R., Moreira SR, Pestana JO Time-dependent changes in cyclosporine exposure: implications for achieving target concentrations. Transplant Int. 2003 ; 16: 494-503.
33. Grevel J., Post BK, Kahan BD Michaelis-Menten kinetics determine cyclosporine steady-state concentrations: a population analysis in kidney transplant patients. Clin Pharmacol Ther. 1993 ; 53: 651-660.
34. Mueller EA, Kovarik JM, van Bree JB, Tetzloff W., Grevel J., Kutz K. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res. 1994 ; 11: 301-304.
35. Kovarik JM, Villamil F., Otero A., et al. Cyclosporine pharmacokinetics and blood pressure responses after conversion to once-daily dosing in maintenance liver transplant patients. Clin Transplant. 2008 ; 22: 68-75.
36. Kajosaari LI, Niemi M., Neuvonen M., Laitila J., Neuvonen PJ, Backman JT Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther. 2005 ; 78: 388-399.
37. Combalbert J., Fabre I., Fabre G., et al. Metabolism of cyclosporin A: IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metab Dispos. 1989 ; 17: 197-207.
38. Fricker G., Drewe J., Huwyler J., Gutmann H., Beglinger C. Relevance of P-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br J Pharmacol. 1996 ; 118: 1841-1847.
39. Lee YJ, Chung SJ, Shim CK Limited role of P-glycoprotein in the intestinal absorption of cyclosporin A. Biol Pharm Bull. 2005 ; 28: 760-763.
40. Perico N., Ruggenenti P., Gaspari F., et al. Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation. Transplantation. 1992 ; 54: 56-60.
41. David-Neto E., Lemos FB, Furusawa EA, et al. Impact of cyclosporin A pharmacokinetics on the presence of side effects in pediatric renal transplantation. J Am Soc Nephrol. 2000 ; 11: 343-349.
42. Filler G., de Barros VR, Jagger JE, Christians U. Cyclosporin twice or three times daily dosing in pediatric transplant patients: it is not the same! Pediatr Transplant. 2006 ; 10: 953-956.
43. Tirona RG, Leake BF, Merino G., Kim RB Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem. 2001 ; 276: 35669-35675.
44. Zhang B., Xie W., Krasowski MD PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics. 2008 ; 9: 1695-1709.
45. Dring MM, Goulding CA, Trimble VI, et al. The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease. Gastroenterology. 2006 ; 130: 341-348.
46. Hauser IA, Schaeffeler E., Gauer S., et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol. 2005 ; 16: 1501-1511.
47. Morris RG, Saccoia NC, Ryall RG, Peacock MK, Sallustio BC Specific enzyme-multiplied immunoassay and fluorescence polarization immunoassay for cyclosporin compared with Cyclotrac [125I]radioimmunoassay. Ther Drug Monit. 1992 ; 14: 226-233.
48. Rodriguez E., Delucchi MA, Cano F., Valdebenito S., Castillo MC, Villegas R. Comparison of cyclosporine concentrations 2 hours postdose determined using 3 different methods and trough level in pediatric renal transplantation. Transplant Proc. 2005 ; 37: 3354-3357.
49. Aspeslet LJ, LeGatt DF, Murphy G., Yatscoff RW Effect of assay methodology on pharmacokinetic differences between cyclosporine Neoral and Sandimmune formulations. Clin Chem. 1997 ; 43: 104-108.
50. Awni WM, Heim-Duthoy K., Kasiske BL Impact of lipoproteins on cyclosporine pharmacokinetics and biological activity in transplant patients. Transplant Proc. 1990 ; 22: 1193-1196.
51. Gardier AM, Mathe D., Guedeney X., et al. Effects of plasma lipid levels on blood distribution and pharmacokinetics of cyclosporin A. Ther Drug Monit. 1993 ; 15: 274-280.
52. Seikku P., Hoppu K., Jalanko H., Holmberg C. Predictive value of pretransplantation cyclosporine pharmacokinetic studies on initial post-transplantation dosing in pediatric kidney allograft recipients. Pediatr Transplant. 2003 ; 7: 102-110.